201 related articles for article (PubMed ID: 24100628)
21. Dasatinib enhances antitumor activity of paclitaxel in ovarian cancer through Src signaling.
Xiao J; Xu M; Hou T; Huang Y; Yang C; Li J
Mol Med Rep; 2015 Sep; 12(3):3249-3256. PubMed ID: 25975261
[TBL] [Abstract][Full Text] [Related]
22. A novel bis-indole destabilizes microtubules and displays potent in vitro and in vivo antitumor activity in prostate cancer.
Ahn S; Hwang DJ; Barrett CM; Yang J; Duke CB; Miller DD; Dalton JT
Cancer Chemother Pharmacol; 2011 Feb; 67(2):293-304. PubMed ID: 20383708
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.
Wang L; Guo B; Wang R; Jiang Y; Qin S; Liang S; Zhao Y; Guo W; Li K; Fan X
Clin Sci (Lond); 2012 Jan; 122(1):13-24. PubMed ID: 21751967
[TBL] [Abstract][Full Text] [Related]
24. A new diaryl urea compound, D181, induces cell cycle arrest in the G1 and M phases by targeting receptor tyrosine kinases and the microtubule skeleton.
Zhang J; Zhou J; Ren X; Diao Y; Li H; Jiang H; Ding K; Pei D
Invest New Drugs; 2012 Apr; 30(2):490-507. PubMed ID: 21080210
[TBL] [Abstract][Full Text] [Related]
25. Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status.
Gaur S; Chen L; Ann V; Lin WC; Wang Y; Chang VH; Hsu NY; Shia HS; Yen Y
Mol Cancer; 2014 Feb; 13():21. PubMed ID: 24495750
[TBL] [Abstract][Full Text] [Related]
26. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
George JA; Chen T; Taylor CC
Cancer Res; 2005 Nov; 65(22):10381-8. PubMed ID: 16288028
[TBL] [Abstract][Full Text] [Related]
27. Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition.
Waters AM; Khatib TO; Papke B; Goodwin CM; Hobbs GA; Diehl JN; Yang R; Edwards AC; Walsh KH; Sulahian R; McFarland JM; Kapner KS; Gilbert TSK; Stalnecker CA; Javaid S; Barkovskaya A; Grover KR; Hibshman PS; Blake DR; Schaefer A; Nowak KM; Klomp JE; Hayes TK; Kassner M; Tang N; Tanaseichuk O; Chen K; Zhou Y; Kalkat M; Herring LE; Graves LM; Penn LZ; Yin HH; Aguirre AJ; Hahn WC; Cox AD; Der CJ
Cell Rep; 2021 Jun; 35(13):109291. PubMed ID: 34192548
[TBL] [Abstract][Full Text] [Related]
28. Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress.
Kopetz S; Lesslie DP; Dallas NA; Park SI; Johnson M; Parikh NU; Kim MP; Abbruzzese JL; Ellis LM; Chandra J; Gallick GE
Cancer Res; 2009 May; 69(9):3842-9. PubMed ID: 19383922
[TBL] [Abstract][Full Text] [Related]
29. Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer.
Xie CY; Xu YP; Jin W; Lou LG
Anticancer Drugs; 2012 Aug; 23(7):698-705. PubMed ID: 22441567
[TBL] [Abstract][Full Text] [Related]
30. Synergistic antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand combined with cisplatin in ovarian carcinoma cell lines in vitro and in vivo.
Liu P; Mao H; Hou P
Int J Gynecol Cancer; 2006; 16(2):538-48. PubMed ID: 16681723
[TBL] [Abstract][Full Text] [Related]
31. Functional roles of Src and Fgr in ovarian carcinoma.
Kim HS; Han HD; Armaiz-Pena GN; Stone RL; Nam EJ; Lee JW; Shahzad MM; Nick AM; Lee SJ; Roh JW; Nishimura M; Mangala LS; Bottsford-Miller J; Gallick GE; Lopez-Berestein G; Sood AK
Clin Cancer Res; 2011 Apr; 17(7):1713-21. PubMed ID: 21300758
[TBL] [Abstract][Full Text] [Related]
32. An antitubulin agent BCFMT inhibits proliferation of cancer cells and induces cell death by inhibiting microtubule dynamics.
Rai A; Surolia A; Panda D
PLoS One; 2012; 7(8):e44311. PubMed ID: 22952952
[TBL] [Abstract][Full Text] [Related]
33. Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells.
Simpkins F; Jang K; Yoon H; Hew KE; Kim M; Azzam DJ; Sun J; Zhao D; Ince TA; Liu W; Guo W; Wei Z; Zhang G; Mills GB; Slingerland JM
Clin Cancer Res; 2018 Oct; 24(19):4874-4886. PubMed ID: 29959144
[No Abstract] [Full Text] [Related]
34. Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma.
Aboukameel A; Muqbil I; Senapedis W; Baloglu E; Landesman Y; Shacham S; Kauffman M; Philip PA; Mohammad RM; Azmi AS
Mol Cancer Ther; 2017 Jan; 16(1):76-87. PubMed ID: 28062705
[TBL] [Abstract][Full Text] [Related]
35. Anti-tumor effects of CIK combined with oxaliplatin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitro.
Zhao Q; Zhang H; Li Y; Liu J; Hu X; Fan L
J Exp Clin Cancer Res; 2010 Aug; 29(1):118. PubMed ID: 20799994
[TBL] [Abstract][Full Text] [Related]
36. Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer.
Chen XX; Xie FF; Zhu XJ; Lin F; Pan SS; Gong LH; Qiu JG; Zhang WJ; Jiang QW; Mei XL; Xue YQ; Qin WM; Shi Z; Yan XJ
Oncotarget; 2015 Jun; 6(17):14926-39. PubMed ID: 25962959
[TBL] [Abstract][Full Text] [Related]
37. Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer.
Hur J; Ghosh M; Kim TH; Park N; Pandey K; Cho YB; Hong SD; Katuwal NB; Kang M; An HJ; Moon YW
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513721
[TBL] [Abstract][Full Text] [Related]
38. Pyrrolotetrazinones deazaanalogues of temozolomide induce apoptosis in Jurkat cell line: involvement of tubulin polymerization inhibition.
Viola G; Cecconet L; Leszl A; Basso G; Brun P; Salvador A; Dall'Acqua F; Diana P; Barraja P; Cirrincione G
Cancer Chemother Pharmacol; 2009 Nov; 64(6):1235-51. PubMed ID: 19363609
[TBL] [Abstract][Full Text] [Related]
39. Mechanisms underlying the cytotoxicity of a novel quinazolinedione-based redox modulator, QD232, in pancreatic cancer cells.
Pathania D; Kuang Y; Sechi M; Neamati N
Br J Pharmacol; 2015 Jan; 172(1):50-63. PubMed ID: 25047070
[TBL] [Abstract][Full Text] [Related]
40. Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis.
Chan CM; Jing X; Pike LA; Zhou Q; Lim DJ; Sams SB; Lund GS; Sharma V; Haugen BR; Schweppe RE
Clin Cancer Res; 2012 Jul; 18(13):3580-91. PubMed ID: 22586301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]